ACTG 081 shows TMP/SMX, aerosolized pentamidine, dapsone have "similar effectiveness" in PCP prevention.
Executive Summary
TMP/SMX, AEROSOLIZED PENTAMIDINE, DAPSONE SHOW "SIMILAR EFFECTIVENESS" in preventing Pneumocystis carinii pneumonia in patients with advanced HIV disease, according to results of the National Institute of Allergy & Infectious Diseases' AIDS Clinical Trials Group protocol 081. The estimated 36-month cumulative risks of PCP in the TMP/SMX, dapsone and aerosolized pentamidine groups are 18%, 17% and 21%, respectively, the investigators found. TMP/SMX is marketed by Hoffmann-La Roche as Bactrim, by Burroughs Wellcome as Septra and in generic versions. Aerosolized pentamidine is marketed by Fujisawa as NebuPent.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth